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Abstract. The development and validation of a liquid chromatography– tandem 
mass spectrometry (LC–MS/MS) method for the determination of adapalene in 
pharmaceutical forms for skin application were presented in this study. The 
MS/MS analysis of adapalene was performed by use of three mobile phases, 
consisted of acetonitrile and a) 0.1 % formic acid, b) 0.1 % trifluoroacetic acid 
and c) 20 mM ammonium acetate. The strongest signals of parent ion and 
dominant product ion were obtained in negative mode by use of the mobile 
phase c). The validation of this method was performed according to the ICH 
guidelines. Small variations of selected chromatographic parameters (concen-
tration of ammonium acetate, mobile phase composition, column temperature 
and flow rate) did not affect significantly the qualitative and quantitative sys-
tem responses, which proved the method’s robustness. The method is specific 
for the determination of adapalene. The linearity was proved in the concentra-
tion range of 6.7–700.0 ng mL-1 (r = 0.9990), with limits of detection and 
quantification of 2.0 and 6.7 ng mL-1, respectively. The accuracy was con-
firmed by calculated recoveries (98.4–101.5 %). The precision was tested at 
three levels: injection repeatability, analysis repeatability and intermediate pre-
cision. The calculated relative standard deviations were less than 1, 2 and 3 %, 
respectively. 
Keywords: adapalene; MS/MS analysis; LC–MS/MS determination; pharma-
ceutical forms for skin application. 
                                                                                                                    
* Corresponding author. E-mail: vladimir@pharmacy.bg.ac.rs 
doi: 10.2298/JSC160215066D 
_________________________________________________________________________________________________________________________Available on line at www.shd.org.rs/JSCS/
(CC) 2016 SCS. All rights reserved.
1172 DOBRIČIĆ et al. 
INTRODUCTION 
Adapalene (Fig. S-1 of the Supplementary material to this paper), chemically 
designated as 6-[3-(1-adamantyl)-4-methoxyphenyl]-2-naphthoic acid, is a third 
generation synthetic retinoid used in the topical treatment of acne vulgaris, 
psoriasis and photo aging.1 The adapalene was quantified by measuring the 
radioactivity in the plasma as well as in other biological samples (urine, faeces 
and skin strips). The measurements showed that its concentrations were below 
the limits of quantification.2 Additionally, no evidence of teratogenicity has been 
reported.3 
Pharmaceutical forms of adapelene are creams, gels, emulsions, microemul-
sions, lotions, soy bean oil-ciclodextrin complexes and solid lipid microparticle 
dispersion.4–6 These forms contain complex matrices and specific and sensitive 
analytical methods are required for adapalene analysis.  
According to the European Pharmacopoeia 7th edition, high performance 
liquid chromatography (HPLC) determination of adapalene is performed by 
using a phenyl column (column length: 250 mm; column diameter: 4.6 mm; par-
ticle size: 5 µm) and mobile phase consisting of glacial acetic acid, water, aceto-
nitrile and tetrahydrofuran.7 Several HPLC methods with UV detection for the 
determination of adapalene in gel topical formulations,8–11 suspensions of nano-
capsules12 and in vitro release studies of adapalene from cream formulation13 
have been reported so far. Rühl and Nau presented a method for the deter-
mination of adapalene and retinol in biological samples that combines solid-phase 
extraction and HPLC with UV and fluorescence detection.14 Brenna et al. used 
mass spectrometry (MS) and gas chromatography–mass spectrometry (GC–MS) 
for the characterization of three adapalene impurities, but these methods were not 
applied to the analysis of adapelene.15 MS has not been applied to the quantific-
ation of adapalene so far and there are no liquid chromatography–mass spectro-
metry (LC–MS) or liquid chromatography–tandem mass spectrometry (LC– 
–MS/MS) methods for the determination of this drug in pharmaceutical forms, 
biological samples, biopharmaceutical and formulation studies. LC–MS and LC– 
–MS/MS are usually used for the analysis of biological samples. However, in the 
last years these methods have been used more often for the analysis of pharma-
ceutical and cosmetic forms (e.g., tablets and creams).16–19  
The goal of this study was to develop and validate a simple, specific and 
sensitive method for the determination of adapalene in pharmaceutical forms for 
skin application (cream, gel and microemulsion). For this purpose, tandem mass 
spectrometry (MS/MS) analysis of adapalene under different ionization condi-
tions was performed and, on the basis of these results, an LC–MS/MS method 
was developed and validated. This method could be used as a starting point for 
the development of a bioanalytical method for the determination of adapalene in 
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biopharmaceutical and pharmacokinetic studies (e.g., estimation of the adapalene 
potential to penetrate the skin using the tape stripping testing technique). 
EXPERIMENTAL 
Details related to chemicals and apparatus used and method optimization are given in 
Supplementary material to this paper. 
Method validation 
The validation of this method was performed according to the ICH guidelines.20 A stan-
dard stock solution was prepared by dissolving 2 mg of adapalene in 100 mL of ethanol (20 
μg mL-1). Subsequently, this solution was diluted with ethanol to obtain working standard 
solutions. Solutions of adapalene formulations (microemulsion APG-1, Sona® 0.1 % gel and 
Sona® 0.1 % cream) were prepared by dissolving these formulations in ethanol (the concen-
tration of adapalene corresponding to 100 % accuracy and precision of the testing was 400 ng 
mL-1). Solutions of placebos were prepared in accordance with the preparation of adapalene 
formulation solutions, which contain adapalene in concentration of 400 ng mL-1. The surfact-
ants and solvents used in the formulation studies were diluted with ethanol prior to injecting.  
The robustness was tested by small variations of selected chromatographic parameters: 
column temperature (23 and 25 °C), flow rate (0.75 and 0.85 mL min-1), concentration of 
ammonium acetate solution (18 and 22 mM) and mobile phase composition (69 and 71 % 
acetonitrile). For this purpose, a mixture of adapalene (400 ng mL-1) and uracil (200 ng mL-1) 
was used. The uracil (LC–MS, negative mode, m/z = 111.0) was used as an unretained 
compound for the calculation of the retention factors (k). The changes in the adapalene peak 
shape, k and peak area (A) were monitored. 
The specificity was tested by injecting an adapalene standard solution (400 ng mL-1), 
placebos, as well as solvents and surfactants used in formulation studies. The chromatograms 
were examined at retention time corresponding to adapalene. 
The limit of detection (LOD) and limit of quantification (LOQ) were concentrations of 
adapalene standard solutions whose signal-to-noise ratios were 3:1 and 10:1, respectively. 
The linearity of the method was tested in the range LOQ – 700 ng mL-1 (LOQ, 67, 250, 
400, 500 and 700 ng mL-1). The influence of different weighting factors (1/x, 1/x2, 1/y and 
1/y2) on the sum of percentage relative error was evaluated and the results were compared with 
an unweighted calibration curve. 
The accuracy was tested by spiking placebo or formulation with standard solution of the 
tested substance to obtain three concentration levels: 80, 100 and 120 % of the target concen-
tration (in this study the target concentration of adapalene was 400 ng mL-1). The accuracy of 
this method was tested by spiking microemulsion APG-1 placebo, Sona® 0.1% gel and Sona® 
0.1 % cream with adapalene standard stock solution (20 μg mL-1) to obtain three concen-
trations (around 320, 400 and 480 ng mL-1) and was evaluated on the basis of calculated rec-
overy values.  
Three levels of method precision (injection repeatability, analysis repeatability and inter-
mediate precision) were tested by analysis of an adapalene microemulsion APG-1, Sona® 0.1 
% gel and Sona® 0.1 % cream at concentration level 100 % (400 ng mL-1). The injection 
repeatability was determined after ten injections of the same sample solution of each formul-
ation. The analysis repeatability was tested by preparing and injecting six sample solutions of 
each formulation, whereas the intermediate precision was tested in the same manner by 
another analyst, another day, with different set of reagents. The precision of the method was 
evaluated by calculating the relative standard deviations of adapalene determinations. 
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RESULTS AND DISCUSSION 
The MS/MS spectra of adapalene, obtained by use of three mobile phases (in 
negative and positive mode) are presented in Figs. 1–3. The applied collision 
energies were 25 (Figs. 3a, 4a and 4b), 30 (Figs. 1b and 2b) and 35 eV (Fig. 1a). 
 
Fig. 1. MS/MS spectra of adapalene, obtained by use of mobile phase acetonitrile/0.1 % 
trifluoroacetic acid (1:1 volume ratio), flow rate: 500 μl min-1, in: a) negative 
and b) positive mode. 
The most dominant fragment ion in negative mode is a product of the ada-
palene decarboxilation (Fig. 4). 
An elimination of both carboxyl and methoxy group could be observed in 
negative mode (m/z 336.7 in Fig. 2a and 337.1 in Fig. 3a), whereas elimination of 
hydroxyl moiety from the carboxyl group was observed in positive mode (m/z 
394.3, Fig. 2b). 
In both negative and positive mode, the fragmentation of adapalene depends 
on the mobile phase used in MS/MS analysis. Additionally, the increase in aceto-
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nitrile content and the decrease in flow rate improved the signal strength of par-
ent ion and product ions. 
 
Fig. 2. MS/MS spectra of adapalene obtained by use of mobile phase acetonitrile/0.1 % formic 
acid (1:1 volume ratio), flow rate: 500 μl min-1, in: a) negative and b) positive mode. 
The strongest signals of parent ion and product ions in positive mode were 
observed when a mobile phase with volume composition acetonitrile/0.1 % tri-
fluoroacetic acid = 50:50 was used. This mobile phase has the lowest pH value 
(pH 2.1) and an efficient protonation of adapalene in positive mode could be 
expected, resulting in the strongest signals of parent ion and product ions. In 
comparison with the negative mode, the signal strength of parent ion and product 
ions in positive mode was significantly lower for all the tested mobile phases.  
The strongest signals of parent ion and product ions in negative mode were 
observed for a mobile phase with volume composition acetonitrile/20 mM 
ammonium acetate = 50:50. This mobile phase has the highest pH value (pH 7.2). 
Therefore, it could be expected that the production of an adapalene anion in 
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negative mode would be the most efficient with this mobile phase, thus resulting 
in the strongest signals of the parent ion and product ions. 
 
Fig. 3. MS/MS spectra of adapalene obtained by use of mobile phase acetonitrile/20 mM 
ammonium acetate  (1:1 volume ratio), flow rate: 500 μl min-1, in: a) negative 
and b) positive mode. 
Among all the tested mobile phases and ionization modes, the strongest sig-
nals of parent ion and most dominant product ion were observed when a mobile 
phase with acetonitrile/20 mM ammonium acetate volume composition of 50:50 
(negative mode, selected reaction monitoring SRM transition: 410.8→367.0) was 
used. Therefore, this mobile phase was selected for further development of the 
method. 
In the next step, the composition of the mobile phase was optimized. A 
simultaneous monitoring of ion 410.8 (LC–MS, negative mode) and SRM tran-
sition 410.8→367.0 (LC–MS/MS, negative mode) was performed and the peak 
parameters (retention time, peak area and peak shape) were analyzed. The inc-
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rease in the percentage of acetonitrile above 70 % led to slight decrease in the 
adapalene retention time, whereas the use of a mobile phase with volume compo-
sition acetonitrile/20 mM ammonium acetate = 90:10 resulted in a peak shape 
deformation. The decrease in the acetonitrile content below 70 % resulted in ada-
palene retention times higher than 10 min, which significantly lengthened the 
analysis. Therefore, the mobile phase with volume composition acetonitrile/20 
mM ammonium acetate = 70:30 and flow rate 0.8 mL min–1 was selected as the 
optimal one. 
 
Fig. 4. Fragmentation of adapalene (negative mode; mobile phase: acetonitrile/20 mM 
ammonium acetate). 
The area of the adapalene peak in LC–MS/MS mode was approximately 
20 % higher than the one obtained by LC-MS and there were no other peaks 
apart from those corresponding to adapalene (Fig. 5). 
 
Fig. 5. LC–MS and LC–MS/MS chromatograms of microemulsion APG-1.  
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This indicated the higher sensitivity and specificity of the LC–MS/MS method. 
Finally, the LC–MS/MS method (negative mode, SRM transition 410.8→  
→367.0) with mobile phase volume composition acetonitrile/20 mM ammonium 
acetate = 70:30, mobile phase flow rate of 0.8 mL min–1 and column temperature 
25 °C was selected as optimal and validated according to the ICH guidelines.20 
Method validation 
Robustness. Small and deliberate changes in the column temperature, flow 
rate, concentration of ammonium acetate solution and mobile phase composition 
affected the retention factors and peak areas with less than 4.80 % (without any 
significant peak shape alterations), which proved the method’s robustness. 
Specificity. The method is specific for the determination of adapalene as no 
interference was observed at retention time corresponding to this substance. 
Overlaid sample chromatograms are presented in Fig. S-2 of the Supplementary 
material. 
Since the specificity was proven by the use of different solvents and exci-
pients, the application of this method to the analysis of adapalene in formulation 
studies (e.g., solubility experiments in tested solvents and excipients, optimiz-
ation of formulation composition and stability evaluation of adapalene topical 
forms) could be considered. 
Limits of detection and quantification. The limits of detection and quantific-
ation were 2.0 and 6.7 ng mL-1, respectively. The LOQ value was used as a first 
point in the linearity testing.  
Linearity. Due to the wide range of expected concentrations in formulation 
studies, the linearity of the method was tested and proved in the range of 6.7 
(LOQ)–700.0 ng mL-1. The selected weighting factor was 1/y2, because its applic-
ation resulted in the lowest sum of percentage relative error (17.63) in compar-
ison to the other weighting factors (18.53–30.20) and unweighted calibration 
curve (115.44). The regression equation was y = 144236x + 526.31 and correl-
ation coefficient (r) was 0.9990. 
Accuracy. The recoveries of adapalene in tested formulations (microemul-
sion APG-1, Sona® 0.1 % gel and Sona® 0.1 % cream) at three concentration 
levels (80, 100 and 120 % of the target concentration) are presented in Table I. 
The recovery at each level is presented as a mean value of three determinations.  
The recoveries were within the specified limits for active pharmaceutical 
ingredients (98–102 %), which proved the method to be accurate for the deter-
mination of adapalene in tested pharmaceutical forms.21 
Precision. The precision was tested at three levels: injection repeatability, 
analysis repeatability and intermediate precision. The results are expressed as rel-
ative standard deviations (RSD, Table II). 
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TABLE I. Recovery values (n = 3) 
Formulation Level % 
Total concen-
tration, ng mL-1 
Found concen-
tration, ng mL-1 
Recovery
% 
RDS 
% 
Microemulsion 
APG-1 
80 328.00 330.69 100.82 1.43 
100 410.00 404.89 98.75 1.31 
120 492.00 499.30 101.48 1.49 
Sona® 0.1% gel 80 320.00 324.67 101.46 1.81 
100 400.00 405.92 101.48 0.78 
120 480.00 484.61 100.96 1.32 
Sona® 0.1 % 
cream 
80 340.00 341.81 100.53 1.11 
100 412.00 411.32 99.83 1.86 
120 484.00 476.16 98.38 1.64 
TABLE II. Precision of the method 
Formulation Level Found concentration, mg g-1 RSD / % 
Microemulsion 
APG-1 
Injection repeatability 1.04 0.86 
Analysis repeatability 1.19 1.83 
Intermediate precision 1.06 2.58 
Sona® 0.1% gel Injection repeatability 0.99 0.81 
Analysis repeatability 1.02 1.19 
Intermediate precision 1.01 2.80 
Sona® 0.1% 
cream 
Injection repeatability 1.04 0.91 
Analysis repeatability 0.98 1.83 
Intermediate precision 0.96 2.05 
The relative standard deviations were within the specified limits for injection 
repeatability (<1 %), analysis repeatability (<2 %) and intermediate precision 
(<3 %), which proved the precision of the method.21 
CONCLUSIONS 
The development and validation of a LC–MS/MS method for the determin-
ation of adapalene in pharmaceutical forms for skin application were presented. 
The MS/MS analysis of adapalene was performed by use of three mobile phases 
(acetonitrile and 0.1 % formic acid; acetonitrile and 0.1 % trifluoroacetic acid; 
acetonitrile and 20 mM ammonium acetate). The strongest signals of parent ion 
and dominant product ion were obtained in negative mode, by use of the mobile 
phase consisting of acetonitrile and 20 mM ammonium acetate. Subsequently, 
optimization of the mobile phase composition and flow rate was performed. The 
method was validated according to the ICH guidelines, which confirmed its 
robustness, specificity, linearity, accuracy and precision. Due to its specificity 
tested by using different solvents and excipients and low LOD and LOQ values, 
application of this method to the analysis of adapalene in formulation studies 
(e.g., solubility experiments in tested solvents and excipients, optimization of 
formulation composition and stability evaluation of adapalene topical forms) 
could be considered. 
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SUPPLEMENTARY MATERIAL 
Details about adapalene, chemicals and apparatus used and metod optimization and spe-
cificity are available electronically at the pages of journal website: http://www.shd.org.rs/  
/JSCS/, or from the corresponding author on request. 
Acknowledgements. The authors would like to acknowledge the financial support from 
the Ministry of Education, Science and Technological Development, Republic of Serbia, through 
Projects OI172041 and TR34031. The authors are grateful to BASF, Kao Chemicals and 
Gattefosse for kindly supplying us with surfactants and solvents. 
И З В О Д  
РАЗВОЈ И ВАЛИДАЦИЈА LC–MS/MS МЕТОДЕ ЗА ОДРЕЂИВАЊЕ АДАПАЛЕНА У 
ФАРМАЦЕУТСКИМ ПРЕПАРАТИМА ЗА ПРИМЕНУ НА КОЖИ 
ВЛАДИМИР ДОБРИЧИЋ1, НАТАША БУБИЋ ПАЈИЋ2, БОЈАН МАРКОВИЋ1, СОТЕ ВЛАДИМИРОВ1, 
СНЕЖАНА САВИЋ3 и ГОРДАНА ВУЛЕТА3 
1Катедра за фармацеутску хемију, Универзитет у Београду, Фармацеутски факултет,  
11000 Београд, 2Катедра за фармацеутску технологију, Универзиет у Бањој Луци, Медицински 
факултет, 78000 Бања Лука, Босна и Херцеговина и 3Катедра за фармацеутску технологију, 
Универзитет у Београд, Фармацеутски факултет, 11000 Београд 
Приказани су развој и валидација методе течне хроматографије са тандем масеном 
спектрометријом (LC–MS/MS) за одређивање адапалена у фармацеутским препаратима 
за примену на кожи. Извршена је MS/MS анализа адапалена употребом три мобилне 
фазе, које су се састоје из ацетонитрила и: а) 0,1 % раствора мравље киселине, b) 0,1 % 
раствора трифлуоросирћетне киселине и c) 20 mM амонијум-ацетата. Најјачи сигнал 
полазног јона и главног фрагмента је добијен у негативном моду употребом мобилне 
фазе c). Валидација методе је извршена према смерницама ICH. Мале промене одаб-
раних хроматографских параметара (концентрација амонијум-ацетата, састав мобилне 
фазе, температура колоне и проток) нису значајно утицале на квалитативне и квантита-
тивне одговоре система, што доказује робусност методе. Метода је специфична за одре-
ђивање адапалена. Линеарност је доказана у опсегу 6,7–700,0 ng mL-1 (r = 0,9990), са 
границама детекције и квантификације од 2,0 и 6,7 ng mL-1, редом. Тачност методе је 
потврђена израчунатим „recovery“ вредностима (98,4–101,5 %). Прецизност је испитана 
на три нивоа: поновљивост инјектовања, поновљивост анализе и средња прецизност. 
Израчунате релативне стандардне девијације су мање од 1, 2 и 3 %, редом. 
(Примљено 15. фебруара, ревидирано 11. маја, прихваћено 27 јуна 2016) 
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